Volpara Health Technologies Limited (VPAHF) — Análisis de acciones con AI
Volpara Health Technologies Limited provides breast imaging analytics software, aiming to improve early breast cancer detection and screening efficiency. Their suite of products leverages AI and data analytics to enhance image quality, assess patient risk, and streamline clinical workflows.
Descripción general de la empresa
Resumen:
Acerca de VPAHF
Tesis de Inversión
Contexto de la Industria
Oportunidades de crecimiento
- Expansion in North America: Volpara has the opportunity to further penetrate the North American market, which represents a significant portion of the global breast cancer screening market. By expanding its sales and marketing efforts and establishing partnerships with leading healthcare providers, Volpara can increase its market share and drive revenue growth. The North American breast cancer screening market is projected to reach billions of dollars in the coming years, offering a substantial growth opportunity for Volpara.
- Product Innovation and AI Development: Continued investment in research and development to enhance its AI-powered software solutions is crucial for Volpara's long-term growth. By developing new features and functionalities, such as improved risk assessment models and personalized screening recommendations, Volpara can strengthen its competitive advantage and attract new customers. The company's Volpara Science division plays a key role in driving product innovation and AI development.
- Strategic Partnerships and Acquisitions: Volpara can pursue strategic partnerships and acquisitions to expand its product portfolio and market reach. By collaborating with complementary technology providers or acquiring companies with innovative solutions in adjacent areas, Volpara can enhance its value proposition and accelerate its growth. The company's existing strategic relationship with RevealDx demonstrates its commitment to partnerships.
- Expansion into Lung Cancer Screening: Leveraging its expertise in medical imaging analytics, Volpara can expand its offerings into lung cancer screening. With the increasing adoption of lung cancer screening programs, there is a growing demand for software solutions that streamline workflows and improve detection rates. Volpara Lung is a step in this direction, and further development in this area could unlock a new growth avenue.
- Data Analytics and Personalized Medicine: Volpara can leverage its vast database of breast imaging data to develop personalized medicine solutions. By analyzing patient data and identifying individual risk factors, Volpara can provide tailored screening recommendations and improve patient outcomes. The growing trend towards personalized medicine presents a significant opportunity for Volpara to differentiate itself and create new revenue streams.
- Market capitalization of $0.19 billion, reflecting its position as a smaller player in the healthcare IT market.
- Negative P/E ratio of -32.34, indicating current lack of profitability but potential for future earnings growth.
- Gross margin of 76.8%, showcasing the high value and pricing power of its software solutions.
- Operating in North America, APAC, and EMEA, demonstrating a global presence and market reach.
- Strategic relationship with RevealDx, potentially enhancing its product offerings and market access.
Qué hacen
- Provides software to optimize breast cancer screening operations.
- Offers real-time image quality feedback during mammography exams.
- Streamlines lung screening workflows.
- Provides customizable mammography reporting and patient communication tools.
- Calculates a patient's risk of developing breast cancer.
- Displays patient breast density and risk insights.
- Powers its software products with AI.
Modelo de Negocio
- Software as a Service (SaaS): Volpara generates revenue through subscription fees for its software solutions.
- Data Analytics: The company leverages its database of breast imaging data to provide analytics and insights to healthcare providers.
- Partnerships: Volpara collaborates with other technology providers to expand its product portfolio and market reach.
- Hospitals and imaging centers
- Breast cancer screening programs
- Healthcare providers
- Proprietary AI Algorithms: Volpara's AI-powered software solutions provide a competitive advantage in terms of accuracy and efficiency.
- Data Network Effects: The company's vast database of breast imaging data creates a network effect, making its solutions more valuable as more data is collected.
- Established Customer Base: Volpara has an established customer base of hospitals, imaging centers, and healthcare providers.
Catalizadores
- Upcoming: Expansion of Volpara's AI-powered solutions into new markets and applications.
- Ongoing: Increasing adoption of breast cancer screening programs globally.
- Ongoing: Strategic partnerships with healthcare providers and technology companies.
- Upcoming: Development of new features and functionalities for Volpara's software solutions.
Riesgos
- Potential: Competition from larger healthcare IT companies with greater resources.
- Potential: Regulatory changes in healthcare impacting reimbursement rates or screening guidelines.
- Potential: Economic downturn leading to reduced healthcare spending.
- Potential: Data security and privacy breaches compromising patient information.
- Ongoing: The company's current lack of profitability and reliance on external funding.
Fortalezas
- Proprietary AI-powered software solutions
- High gross margin
- Established customer base
- Global presence
Debilidades
- Negative profit margin
- Reliance on subscription revenue
- Limited brand recognition compared to larger competitors
- OTC listing may limit investor access
Oportunidades
- Expansion in North America and Europe
- Product innovation and AI development
- Strategic partnerships and acquisitions
- Expansion into lung cancer screening
Amenazas
- Competition from larger healthcare IT companies
- Regulatory changes in healthcare
- Economic downturn impacting healthcare spending
- Data security and privacy concerns
Competidores y Pares
- Accenture — Offers broad healthcare consulting and technology services. — (ADOCY)
- Allscripts Healthcare Solutions — Provides electronic health record (EHR) and practice management solutions. — (AMGXF)
- athenahealth — Offers cloud-based EHR, revenue cycle management, and patient engagement solutions. — (BRNHF)
- Cerner Corporation — Provides healthcare information technology solutions and services. — (DLHTF)
- Elevance Health — Offers a range of healthcare plans and services. — (EKDHF)
Key Metrics
- Volume: 0
- MoonshotScore: 60/100
Company Profile
- CEO: Teri Jo Thomas
- Headquarters: Wellington, NZ
- Employees: 156
- Founded: 2018
AI Insight
- OTC Tier: OTC Other
- Disclosure Status: Unknown
Preguntas y respuestas
What does Volpara Health Technologies Limited do?
Volpara Health Technologies Limited specializes in developing and providing AI-powered breast imaging analytics software. Their solutions are designed to optimize breast cancer screening operations, improve image quality, assess patient risk, and streamline clinical workflows. The company's products, such as Volpara Analytics and Volpara Risk, are used by hospitals, imaging centers, and healthcare providers to enhance early breast cancer detection and personalized screening programs. Volpara operates globally, serving customers in North America, the Asia Pacific, Europe, the Middle East, and Africa.
What do analysts say about VPAHF stock?
As of 2026-03-16, a comprehensive analyst consensus on VPAHF stock is not available within the provided data. Investors should conduct their own due diligence and consult with financial professionals to assess the company's valuation, growth prospects, and risk factors. Key metrics to consider include the company's market capitalization, revenue growth, gross margin, and profitability. The company's position in the healthcare information services industry and its competitive landscape should also be taken into account.
What are the main risks for VPAHF?
Volpara Health Technologies Limited faces several risks, including competition from larger healthcare IT companies, regulatory changes in healthcare, economic downturns impacting healthcare spending, and data security and privacy breaches. The company's current lack of profitability and reliance on external funding also pose risks to its financial stability. Additionally, as an OTC-listed stock, VPAHF is subject to greater liquidity risk and price volatility compared to stocks listed on major exchanges. Investors should carefully consider these risks before investing in VPAHF.
Is VPAHF a good investment right now?
Use the AI score and analyst targets on this page to evaluate Volpara Health Technologies Limited (VPAHF). Our analysis considers fundamentals, technicals, and market sentiment to help you decide.
What is the MoonshotScore for VPAHF?
The MoonshotScore is a proprietary 0-100 AI rating that evaluates Volpara Health Technologies Limited across multiple dimensions including financial health, growth trajectory, and risk factors.
Where can I find VPAHF financial statements?
Volpara Health Technologies Limited financial data including revenue, earnings, and balance sheet metrics are available in the Financials tab on this page, sourced from institutional-grade data providers.
What do analysts say about VPAHF?
Analyst consensus targets and ratings for Volpara Health Technologies Limited are shown in the analysis section. These are aggregated from major Wall Street firms and updated regularly.
How volatile is VPAHF stock?
Check the beta and historical price range on this page to assess Volpara Health Technologies Limited's volatility relative to the broader market.